Paul Dohrenwend

Paul Dohrenwend has a diverse work experience in various fields. Paul is currently a Venture Partner at SpringTide Ventures since February 2022. Prior to that, they served as the Chief Executive Officer of SAFU SAKE starting from August 2019. Before their entrepreneurial ventures, Paul worked at the Southern California Permanente Medical Group as a Partner Physician, Assistant Chief of Emergency Medicine, Chief of Emergency Medicine/Chairman Academics, and Director of Physician Education. Their tenure at the medical group started in October 2006 and continued until April 2022. Furthermore, Paul served as an Investor at the San Diego Angel Conference from February 2019 to June 2020. Paul began their career as a Research Assistant at Harvard Medical School and Massachusetts General Hospital, where they conducted research on creating a vaccine for HCV using cytotoxic T-cells under the guidance of Dr. David Whong in Dr. Bruce Walker's lab from 1997 to 1999.

Paul Dohrenwend's education history begins with their enrollment at Georgetown University School of Medicine, where they pursued a Doctor of Medicine (MD) degree from 1999 to 2003. During this period, they focused on health/health care administration/management.

Prior to their medical studies, Dohrenwend obtained a Bachelor of Science (BS) degree in Biology, General from Georgetown University. This undergraduate program took place from 1993 to 1997.

Later in their education journey, Dohrenwend pursued a Master of Business Administration (MBA) at The Wharton School. From 2019 to 2021, they underwent a comprehensive program focused on finance, strategy, and marketing.

It is worth noting that the exact start and end years for Paul Dohrenwend's second MD degree from Georgetown University School of Medicine are not provided. However, the degree field of study is unknown as well.